During 2022, the ENT department focused on the well-being of the patients in all sub-disciplines of our specialty. First, we were pleased to obtain reimbursement of long-awaited biological products for the treatment of patients with chronic rhinosinusitis with nasal polyps. These new therapies are able to help a significant number of patients whose disease cannot be controlled by standard medical and surgical treatments. Second, we were able to review a series of more than 250 patients who underwent parotidectomy with intraoperative neuromonitoring. We found that preservation of facial nerve function was significantly better compared with previously reported data on parotidectomies without neuromonitoring. Finally, in the field of cochlear implantation for patients with severe hearing loss, we are currently preparing for the future. New techniques have been developed in order to maintain residual hearing during the implant’s insertion into the cochlea, such as robotic surgery and intraoperative electrocochleography. These techniques will allow us to increase the indications for implantation, which will lead to more patients being able to benefit from this life-changing technology.
Key Words
Parotidectomy, facial nerve intraoperative monitoring, chronic rhinosinusitis, nasosinus polyposis, biotherapy, cochlear implant, peroperative electrocochleography